Lancet:非洲手术患者的术后并发症、死亡情况。

2018-01-04 MedSci MedSci原创

非洲国家需增加手术治疗的机会,但围手术期并发症是全球卫生保健的主要负担。Bruce M Biccaard等人在非洲的25个国家进行一为期7天的前瞻性、观察性队列研究,研究年满18岁的将进行住院手术的任何疾病的患者。为尽可能用便利抽样招募尽可能多的医院,要求每个国家至少有10家医院提供数据,而且每个来源的数据至少90%可用。主要评估指标是住院期间的术后并发症。2016年2月-5月,共从247家医院招

非洲国家需增加手术治疗的机会,但围手术期并发症是全球卫生保健的主要负担。

Bruce M Biccaard等人在非洲的25个国家进行一为期7天的前瞻性、观察性队列研究,研究年满18岁的将进行住院手术的任何疾病的患者。为尽可能用便利抽样招募尽可能多的医院,要求每个国家至少有10家医院提供数据,而且每个来源的数据至少90%可用。主要评估指标是住院期间的术后并发症。

2016年2月-5月,共从247家医院招募11 422位患者,医院的中位人口810 000(IQR 200 000-2 000 000),其中专业外科医生、产科医生和麻醉师加起来约0.7(0.2-1.9)/100 000人。医院每年每100 000人约做手术中位值212台(IQR 65-578)。患者年龄较高收入国家患者年龄低(平均年龄38.5岁[SD 16.1]),风险较低(美国麻醉学协会评分平均1分[1-2])。1253位(11%)患者感染HIV,6504台(57%)手术为急诊手术,其中多是剖腹产手术(3792人,33%)。10 885位患者中有1977位(18.2%,95% CI 17.4-18.9)出现术后并发症。11 193位患者中有239人(2.1%)死亡,其中225例(94.1%)是在手术日之后。感染是最常见的并发症(1156[10.2%]/10 970),其中112人(9.7%)死亡。

尽管风险低、术后并发症少,但非洲患者术后死亡的风险是全球术后死亡平均风险的两倍。在努力增加非洲手术治疗的机会的同时,尽可能提高术后患者的存活率。

原始出处:

Bruce M Biccaard,et al.Perioperative patient outcomes in the African Surgical Outcomes Study: a 7-day prospective observational cohort study.The Lancet. January 03,2018. http://dx.doi.org/10.1016/S0140-6736(18)30001-1

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1829407, encodeId=7c1e182940e4f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Oct 01 06:50:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757920, encodeId=fa161e5792006, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Fri Feb 02 03:50:00 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275805, encodeId=c4dd2e580589, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Fri Jan 05 21:33:09 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275728, encodeId=0c772e57285f, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Jan 05 12:58:25 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275455, encodeId=20262e545594, content=谢谢分享.学习受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Jan 04 18:23:26 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275447, encodeId=98082e544758, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Thu Jan 04 18:11:53 CST 2018, time=2018-01-04, status=1, ipAttribution=)]
    2018-10-01 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1829407, encodeId=7c1e182940e4f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Oct 01 06:50:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757920, encodeId=fa161e5792006, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Fri Feb 02 03:50:00 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275805, encodeId=c4dd2e580589, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Fri Jan 05 21:33:09 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275728, encodeId=0c772e57285f, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Jan 05 12:58:25 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275455, encodeId=20262e545594, content=谢谢分享.学习受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Jan 04 18:23:26 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275447, encodeId=98082e544758, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Thu Jan 04 18:11:53 CST 2018, time=2018-01-04, status=1, ipAttribution=)]
    2018-02-02 丁鹏鹏
  3. [GetPortalCommentsPageByObjectIdResponse(id=1829407, encodeId=7c1e182940e4f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Oct 01 06:50:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757920, encodeId=fa161e5792006, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Fri Feb 02 03:50:00 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275805, encodeId=c4dd2e580589, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Fri Jan 05 21:33:09 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275728, encodeId=0c772e57285f, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Jan 05 12:58:25 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275455, encodeId=20262e545594, content=谢谢分享.学习受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Jan 04 18:23:26 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275447, encodeId=98082e544758, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Thu Jan 04 18:11:53 CST 2018, time=2018-01-04, status=1, ipAttribution=)]
    2018-01-05 杨柳青青

    签到学习了--

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1829407, encodeId=7c1e182940e4f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Oct 01 06:50:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757920, encodeId=fa161e5792006, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Fri Feb 02 03:50:00 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275805, encodeId=c4dd2e580589, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Fri Jan 05 21:33:09 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275728, encodeId=0c772e57285f, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Jan 05 12:58:25 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275455, encodeId=20262e545594, content=谢谢分享.学习受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Jan 04 18:23:26 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275447, encodeId=98082e544758, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Thu Jan 04 18:11:53 CST 2018, time=2018-01-04, status=1, ipAttribution=)]
    2018-01-05 1dd8c52fm63(暂无匿称)

    学习学习.继续关注

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1829407, encodeId=7c1e182940e4f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Oct 01 06:50:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757920, encodeId=fa161e5792006, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Fri Feb 02 03:50:00 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275805, encodeId=c4dd2e580589, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Fri Jan 05 21:33:09 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275728, encodeId=0c772e57285f, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Jan 05 12:58:25 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275455, encodeId=20262e545594, content=谢谢分享.学习受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Jan 04 18:23:26 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275447, encodeId=98082e544758, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Thu Jan 04 18:11:53 CST 2018, time=2018-01-04, status=1, ipAttribution=)]
    2018-01-04 清风拂面

    谢谢分享.学习受益匪浅

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1829407, encodeId=7c1e182940e4f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Oct 01 06:50:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757920, encodeId=fa161e5792006, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Fri Feb 02 03:50:00 CST 2018, time=2018-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275805, encodeId=c4dd2e580589, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Fri Jan 05 21:33:09 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275728, encodeId=0c772e57285f, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Jan 05 12:58:25 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275455, encodeId=20262e545594, content=谢谢分享.学习受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Jan 04 18:23:26 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275447, encodeId=98082e544758, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Thu Jan 04 18:11:53 CST 2018, time=2018-01-04, status=1, ipAttribution=)]
    2018-01-04 Y—xianghai

    学习了新知识

    0

相关资讯

Lancet Infect Dis:A型脑膜炎疫苗非洲应用效果评估

MenAfriVac 接种大幅减少了脑膜炎流行发病率,要继续加强疫苗的性能监测并对其他脑膜炎球菌血清群和其他病原体的严重威胁保持警惕

Thorax:在非洲治疗耐药结核病已获得了突破性的进展

背景:报道称在非洲具有不良预后的耐药肺结核(MDR-TB)合并HIV感染的患者,经过治疗后中只有不到一半被成功治愈。方法:在埃塞俄比亚的一个非政府组织的社区性卫生部(NGO-MOH)里,以医院为同标准的治疗程序,使用标准的二线药物(SLD),进行严密的副作用监测,并坚持治疗与营养支持。跟踪随访至少24个月,记录病人的临床结局,回顾和预测治疗失败或死亡的结局,使用Cox 比例风险模型分析。结果:从2

N Engl J Med:非洲本地恶性疟原虫对青蒿素抗性的出现

青蒿素是在大多数国家是治疗疟疾的一线药物,在疟疾流行的非洲其作用显得尤为重要。然而随着恶性疟原虫已经在东南亚的许多国家对青蒿素的抗性的出现,国际社会开始高度关注青蒿素在非洲的抗性情况。在赤道几内亚,疟疾流行率一直很高,青蒿素联合治疗作为最常用的治疗方式。在赤道几内亚和具有类似疟疾传播的非洲国家中,应该警惕非洲恶性疟对青蒿素的耐药性,监测潜在的青蒿素抗性出现。

Neurology:神经急救SOP在撒哈拉以南非洲的应用

执行标准操作程序是一个现实的,低成本的提高不发达地区神经急救过程质量的方法

Lancet Infect Dis:5岁以下儿童百日咳流行病学研究

相比于1999-2003年的统计(3060万的5岁以下儿童病例以及390000死亡),百日咳病例数及死亡人数均显著下降。

NEJM:非洲疟疾死亡率研究(1990-2015年)

本研究合并了“疟疾地图计划(Malaria Atlas Project)”和“全球疾病负担研究(Global Burden of Disease Study)”的数据,对1990年到2015年,撒哈拉以南非洲5平方公里地区范围内的疟疾死亡率进行了评估。 在过去的15年时间里,撒哈拉以南的非洲其整体疟疾死亡人数比例下降了57%(95%的不确定性区间,46到65),从2000年的12.5(95%